Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$3.43 USD
+0.07 (2.08%)
Updated Aug 15, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Pyxis Oncology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -73.79 | -120.72 | -75.98 | -12.83 | NA |
Depreciation/Amortization & Depletion | -2.86 | 0.71 | 0.65 | 0.47 | NA |
Net Change from Assets/Liabilities | -11.66 | 4.50 | 6.68 | 1.87 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 17.61 | 26.17 | 33.33 | 0.41 | NA |
Net Cash From Operating Activities | -70.71 | -89.34 | -35.33 | -10.08 | NA |
Property & Equipment | -6.73 | -6.40 | -0.54 | -1.48 | NA |
Acquisition/ Disposition of Subsidiaries | 6.66 | 0.00 | 0.00 | 0.00 | NA |
Investments | -104.78 | 0.00 | -0.05 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | -0.05 | 0.00 | NA |
Net Cash from Investing Activities | -104.85 | -6.40 | -0.59 | -1.48 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.37 | 0.18 | 304.04 | 0.04 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -0.45 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | 5.93 | 0.18 | 304.04 | 0.04 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -169.63 | -95.55 | 268.13 | -11.53 | NA |
Cash at Beginning of Period | 180.77 | 276.32 | 8.19 | 19.72 | NA |
Cash at End of Period | 11.14 | 180.77 | 276.32 | 8.19 | NA |
Diluted Net EPS | -1.85 | -3.65 | -8.95 | NA | NA |
Fiscal Year End for Pyxis Oncology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -3.26 | -73.79 | -58.19 | -35.14 |
Depreciation/Amortization & Depletion | NA | -0.17 | -2.86 | -2.11 | -1.15 |
Net Change from Assets/Liabilities | NA | -21.77 | -11.66 | -9.36 | -10.45 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 4.48 | 17.61 | 14.20 | 8.87 |
Net Cash From Operating Activities | NA | -20.71 | -70.71 | -55.46 | -37.87 |
Property & Equipment | NA | -0.24 | -6.73 | -6.73 | -6.67 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 6.66 | 6.66 | 0.00 |
Investments | NA | -18.26 | -104.78 | -115.01 | -114.98 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -18.50 | -104.85 | -115.08 | -121.65 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 57.71 | 6.37 | 6.35 | 6.13 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.20 | -0.45 | -0.39 | 0.00 |
Net Cash from Financing Activities | NA | 57.51 | 5.93 | 5.95 | 6.13 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 18.30 | -169.63 | -164.58 | -153.40 |
Cash at Beginning of Period | NA | 11.14 | 180.77 | 180.77 | 180.77 |
Cash at End of Period | NA | 29.44 | 11.14 | 16.19 | 27.37 |
Diluted Net EPS | NA | -0.06 | -0.34 | -0.56 | -0.41 |